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Measurement of SO Release From Rat PMNs 
The SO release from PMNs was measured spectrophotometrically (model 260 Gilford, Nova 
Biotech; El Cajon, CA) by the reduction of ferricytochrome c (4). The PMNs (5 x106) were 
resuspended in 450 μl PBS and incubated with ferricytochrome c (100 µM, Sigma Chemical) in a 
total volume of 900 μl PBS in the presence or absence of  mitoQ (1-20 µM) or other CoQ analogs 
(10-80 µM) for 15 min at 37oC in spectrophotometric cells. The PMNs were stimulated with 100 
nM PMA (Sigma Chemical) or 1 μM fMLP (Calbiochem) in a final reaction volume of 1.0 ml. 
Positive control samples were given SO dismutase (SOD; 10 μg/ml) just before the addition of 
PMA or fMLP.  Absorbance at 550 nm was measured every 30 sec for up to 360 sec (peak 
response)  for PMA and 180 sec for fMLP (peak response), and the change in absorbance (SO 
release) from PMNs was determined relative to time 0. 
 
Cell Viability 
Cell viability was determined by combining 0.5 ml of the samples from spectrophotometric 
analysis and 50 μl of 0.3% Trypan Blue.  Then, 20 μl of the combined sample was placed on to a 
hemocytometer, and 100-150 cells were subsequently counted using microscopic analysis 
 
Statistical Analysis 
All data in the text and figures are presented as means ± S.E.M. The data were analyzed by 
analysis of variance using post hoc analysis with the Student-Newman-Keuls test.  Probability 
values of ≤0.05 are considered to be statistically significant. 
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Figure 1. Schematic representation of PKC activation generating SO release in a PMN. PMN chemotactic G-protein 
receptors are activated by fMLP, complement C5a, and IL-8. The G-protein subunits αq and βγ disassociate after 
stimulation and activate phospholipase C beta (PLCβ) and phosphatidyl inositol-3-kinase gamma (PI-3kinγ) to produce 
inositol 1,4,5 trisphosphate (Ins(1,4,5)P2) plus diacylglycerol (DAG) and PtdIns(3,4,5)P2 respectively from phospholipids 
phosphatidylinositol 4,5 bisphosphate (PtdIns(4,5)P2). Ins(1,4,5)P2 stimulates Ca2+ release from the endoplasmic 
reticulum (ER). Ca2+/DAG and PtdIns(3,4,5)P2 directly activate PKC. PMA directly activates PKC.  Activated PKC 
phosphorylates NADPH oxidase to release SO anion (O2-)   Adapted from (1). 
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Figure 3. The dose-dependent effects of MitoQ on PMA (100 nM) and fMLP (1μM)-induced SO release in PMNs. The peak 
response in PMA -induced SO release (left). The peak response in fMLP -induced SO release (right).  MitoQ (10μM) and mitoQ (20μM) 
significantly attenuated PMA-induced PMN SO release by 45% (*P<0.05) and 79% (**P<0.01) respectively compared to PMA. MitoQ 
(5μM) and mitoQ (10μM) significantly attenuated fMLP-induced PMN SO release by 90% (*P<0.05) and 90% (*P<0.05) respectively 
compared to fMLP.  SOD served as a positive control inhibiting PMA-induced SO release by >90% (n=8; absorbance = 0.045 + 0.005) 
and fMLP-induced SO release by >90% (n=9; absorbance = 0.010 + 0.004). 
. 
 
Figure 7. The Effects of CoQ analogs on Cell Viability in PMA (100 nM) and fMLP (1 μM)-induced SO release in 
PMNs.  Cell Viability in PMA -induced SO release (left).  Cell Viability in fMLP -induced SO release (right).  MitoQ (20μM) 
significantly attenuated cell viability by 28% (**P<0.01) compared to PMA.  MitoQ (10μM)  significantly attenuated cell 
viability by 19% (*P<0.05) compared to fMLP.   
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Figure 2. Illustration of the reduced and oxidized form of mitoQ and CoQ analogs.  The reduced form, ubiquinol, acts as 
an antioxidant free radical scavenger via hydrogen atom transfer.     
  
PMNs have been identified as one of the main mechanisms underlying ischemia reperfusion (I/R) 
injury.  Their tendency to injure the myocardium, coronary endothelium, and myocytes is caused by 
proinflammatory mediators such as tumor necrosis factor α and interleukin 8.   PMNs contain an 
extensive cytotoxic arsenal and their potential to destroy tissue is caused by degranulation and 
generation of reactive oxygen species (ROS).  The activation of the PMN membrane-associated 
NADPH oxidase system by proinflammatory cytokines, C5a, platelet activating factor, and particulate 
stimuli initiates a respiratory burst characterized by a marked increase in cellular oxygen consumption 
and the generation of SO anions.  Protein kinase C (PKC) activation of PMN NADPH oxidase is 
essential to generate PMN SO release (1).  fMLP peptide activates PMN chemotactic receptor to 
stimulate NADPH oxidase via PKC.  PMA is a lipid soluble broad spectrum PKC agonist that directly 
activates PKC (Fig. 1).  Inhibition of PMN SO release attenuates inflammation mediated vascular 
injury (e.g. I/R). 
Ubiquinones, coenzyme Q (CoQ), are stoichiometrically in excess of electron-transfer chains, and it 
has been suggested that in addition to their role in mitochondrial respiration, ubiquinones in their 
reduced form, ubiquinols, may act as free radical scavengers.  MitoQ, a mitochondria-targeted CoQ 
antioxidant analog, dose-dependently (1-20 µM) restored post-reperfused cardiac function and reduced 
infarct size in isolated perfused rat hearts subjected to I/R (2).  Accumulation of ubiquinol within 
mitochondria is necessary for the efficacy of mitoQ in limiting myocardial I/R injury (3).  Given that 
NADPH oxidase is the principal source of PMN SO release, we speculated that mitoQ may exert some 
of its antioxidant effects independent of the mitochondria. 
MitoQ and CoQ10 dose-dependently attenuated both PMA and fMLP-induced SO release in 
PMNs. DQ and CoQ1 significantly augmented the fMLP-induced PMN SO release.  
Whereas, CoQ1 dose-dependently significantly attenuated PMA-induced SO release, DQ 
showed a trend to decrease the PMA-induced response. CoQ4 had no significant effect on 
PMA or fMLP-induced PMN SO release (data not shown).  MitoQ significantly decreased 
cell viability in both PMA (20 µM) and fMLP (10 µM) stimulated PMNs. CoQ1, CoQ4, 
CoQ10, and DQ had no significant effect on cell viability.  
     
We hypothesized that MitoQ and other CoQ analogs would dose-dependently attenuate both PMA and 
fMLP induced SO release in PMNs without affecting cell viability. 
Isolation of PMNs 
Male Sprague-Dawley rats (350–400 g, Charles River, Springfield, MA), used as PMN donors, 
were anesthetized with isoflurane and given a 16 ml intraperitoneal injection of 0.5% glycogen 
(Sigma Chemical) dissolved in PBS. Rats were reanesthetized with isoflurane 16–18 h later, and 
the PMNs were harvested by peritoneal lavage in 30 ml of 0.9% NaCl, as previously described (4). 
The peritoneal lavage fluid was centrifuged at 200 g for 10 min at 4oC. The PMNs were then 
washed in 20 ml PBS and centrifuged at 200 g for 10 min at 4oC. Thereafter, the PMNs were 
resuspended in 2.5 ml PBS and concentration was calculated. The PMN preparations were >90% 
pure and >95% viable according to microscopic analysis and exclusion of 0.3% trypan blue, 
respectively.  
 
  
Figure 4. The dose-dependent effects of CoQ10 on  PMA (100 nM) and fMLP (1μM)-induced SO release in PMNs. The peak 
response in PMA -induced SO release (left). The peak response in fMLP-induced SO release (right). CoQ10 (80μM) significantly 
attenuated PMA-induced PMN SO release by 41% (*P<0.05) compared to PMA. CoQ10 (40μM) and CoQ10 (80μM) significantly 
attenuated fMLP-induced PMN SO release by 61% (*P<0.05) and 51% (*P<0.05) respectively compared to fMLP.    
Decylubiquinone (DQ) 
Conclusions 
These results suggested that mitoQ exerted its antioxidant effects independent of the 
mitochondria and were related in part to cell viability. CoQ10 exerted its antioxidant effects 
independent of cell viability and suggests that the quinone group of the molecule was 
converted into its reduced form. DQ and CoQ1 exerted pro-oxidant effects in fMLP 
stimulated PMNs perhaps by augmenting receptor-mediated signal transduction causing 
NADPH oxidase activation. Whereas, CoQ1 exerted dose-dependent inhibition of PMA-
induced PKC activation of NADPH oxidase . 
Figure 5. The dose-dependent effects of  DQ on PMA (100 nM) and fMLP (1μM)-induced SO release in PMNs. The 
peak response in PMA -induced SO release (left). The peak response in fMLP -induced SO release (right).  DQ did not 
significantly affect the PMA-induced SO release.  DQ (10μM), DQ (40μM), and DQ (80μM) significantly augmented 
fMLP-induced PMN SO release by 73% (**P<0.01), 92% (**P<0.01), and 98% (**P<0.01) respectively compared to fMLP.  
Figure 6. The dose-dependent effects of  CoQ1 on PMA (100 nM) and fMLP (1μM)-induced SO release in PMNs. The 
peak response in PMA -induced SO release (left). The peak response in fMLP -induced SO release (right). CoQ1 (40μM) and 
CoQ1 (80μM) significantly attenuated PMA-induced PMN SO release by 48% (**P<0.01) and 67% (**P<0.01) respectively 
compared to PMA. CoQ1 (40μM) significantly augmented fMLP-induced PMN SO release by 84% (**P<0.01) compared to 
fMLP.  
